Celldex ax­es two more pro­grams to cut costs fol­low­ing glem­bat­u­mum­ab fail­ure; Zio­pharm stock slides on halt­ed brain can­cer tri­al

→ New Jer­sey-based biotech Celldex $CLDX is cut­ting two pro­grams from its pipeline, hoard­ing re­sources af­ter the fail­ure of its lead breast can­cer drug glem­bat­u­mum­ab in late April. The com­pa­ny is ax­ing its Phase I re­nal cell and clear cell ovar­i­an car­ci­no­ma drug CDX-014, along with its CDX-1401 pro­gram, an off-the-shelf den­drit­ic cell-tar­get­ing vac­cine.

“Celldex has made con­sid­er­able progress on an im­por­tant strate­gic pri­or­i­ti­za­tion of our pipeline, fol­low­ing (the)…dis­con­tin­u­a­tion of the glem­bat­u­mum­ab pro­gram across all in­di­ca­tions,” said An­tho­ny Maruc­ci, co-founder, pres­i­dent and CEO of Celldex Ther­a­peu­tics, in a state­ment. “In 2018, we will fo­cus pri­mar­i­ly on con­tin­ued clin­i­cal de­vel­op­ment of two com­pa­ny-spon­sored pro­grams — CDX-1140, a promis­ing CD40 ag­o­nist, and CDX-3379, which blocks ErbB3, a re­cep­tor thought to play an im­por­tant role in reg­u­lat­ing can­cer cell growth and sur­vival.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.